SelectION's si-544 Demonstrates Disease-Modifying Potential in Phase 1b Psoriasis Trial
核心洞察
SelectION (搜索)'s si-544, a first-in-class Kv1.3 (搜索) channel blocker, achieved statistically significant improvements in PASI scores compared to placebo in a Phase 1b trial of 45 psoriasis (搜索) patients.
The drug demonstrated excellent safety and tolerability with no dose-limiting toxicities or serious adverse events, while maintaining full immunocompetence in treated patients.
A short 4-week treatment cycle resulted in durable clinical improvements that continued throughout a 12-week post-treatment monitoring period, suggesting disease-modifying potential.
SelectION (搜索), Inc. has announced successful completion of its Phase 1b proof-of-concept trial evaluating si-544, a first-in-class Kv1.3 (搜索) blocker, in patients with psoriasis vulgaris (搜索). The randomized, double-blind, placebo-controlled study demonstrated statistically significant clinical improvements and excellent safety profile, marking what the company describes as the first clinical validation of Kv1.3 as a therapeutic target in T cell-mediated autoimmunity.
Novel Mechanism Targets Autoimmune Disease Root Cause
The voltage-gated potassium ion channel Kv1.3 (搜索) represents a well-researched clinical target in autoimmunity, with dependency on this channel being a distinct feature of autoreactive T cells. si-544 works by selectively blocking Kv1.3, which irreversibly disrupts the pathogenic activity of chronically activated, autoreactive T cell clones while maintaining patients' protective immunocompetence.
"These results mark a significant milestone, as si-544 has, for the first time, clinically confirmed the long hypothesized and remarkable therapeutic potential of Kv1.3 (搜索) in T cell autoimmunity," said Antonius Schuh, Ph.D., CEO of selectION (搜索). "This trial clinically validates Kv1.3 dependency as an ideal clinical entry point to disrupt the chronic activation of pathogenic, autoreactive T cells."
Phase 1b Trial Design and Patient Population
The study enrolled 45 patients across four clinical sites in Germany, with participants diagnosed with mild-to-severe psoriasis vulgaris (搜索). Patients received two subcutaneous injections of si-544 or placebo per week in a 3:1 ratio over four weeks, followed by a 12-week post-treatment monitoring period.
The primary objective focused on evaluating safety and tolerability through monitoring of adverse events, laboratory findings, ECG results, and vital signs. Secondary endpoints included pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy measures using psoriasis (搜索) area and severity index (PASI), physician's global assessment (PGA), and body surface area (BSA).
Significant Clinical Improvements with Excellent Safety Profile
The trial demonstrated that a short 4-week treatment cycle resulted in statistically significant clinical improvement as measured by changes in PASI scores (P< .05) compared to placebo. Clinical efficacy signals emerged as early as week 2 of the treatment period, with disease stabilization and continued healing observed throughout the entire 12-week monitoring period following drug washout.
si-544 demonstrated excellent safety and tolerability, with no related serious adverse effects, dose-limiting toxicities, or safety signals observed. Importantly, patients treated with si-544 maintained full immunocompetence throughout the study period, indicating the drug's selective targeting mechanism does not compromise overall immune function.
Disease-Modifying Potential Across Multiple Indications
The observed durable clinical improvement and continued healing beyond drug exposure demonstrates the disease-modifying quality of the clinical response. This mechanism supports the hypothesis that short treatment cycles with si-544 could induce durable, disease-modifying effects across a wide range of autoimmune conditions, including atopic dermatitis (搜索), rheumatoid arthritis (搜索), inflammatory bowel disease (搜索), and multiple sclerosis (搜索).
"This Phase 1b study confirms our central development hypothesis that si-544, a potent and highly selective Kv1.3 (搜索) blocker, can safely achieve specific disruption of disease-driving autoreactive T cells without compromising the patient's immune competence," said Andreas Klostermann, Ph.D., CSO and scientific founder of selectION (搜索). "The results observed in psoriasis (搜索) echo the results from our first-in-human study in atopic dermatitis (搜索), and we are now focused on advancing the clinical development of si-544 across multiple autoimmune indications."
Clinical Development Strategy
si-544 has previously demonstrated an excellent safety and tolerability profile in completed Phase 1b clinical trials in atopic dermatitis (搜索) patients, with an initial efficacy signal observed in that indication. The company describes si-544 as a potent immuno-selective agent addressing significant unmet medical need by functionally inhibiting and eliminating disease-specific, chronically activated effector memory T cells while maintaining full immunocompetence.
The successful psoriasis (搜索) trial represents clinical proof of concept for the Kv1.3 (搜索) targeting approach, with the company now focused on advancing clinical development across multiple autoimmune indications where chronically activated autoreactive effector memory T cells drive disease pathology.